Search research articles
Contact Us
Filters
Showing results (201-210 of 224) with videos related to
Page
of 23
Sort By:
The Journal of Experimental Medicine
|
August 3, 2021
ASC deglutathionylation is a checkpoint for NLRP3 inflammasome activation
Shuhang Li, Linlin Wang, Zhihao Xu, et al.
Nature Communications
|
April 22, 2022
USP22 regulates lipidome accumulation by stabilizing PPARγ in hepatocellular carcinoma
Zhen Ning, Xin Guo, Xiaolong Liu, et al.
Lung Cancer (Amsterdam, Netherlands)
|
September 13, 2025
Chinese expert consensus on perioperative management of patients with resectable anaplastic lymphoma kinase-fusion non-small cell lung cancer
Hai-Yan Tu, Chun Chen, Chang Chen, et al.
The Lancet Regional Health. Western Pacific
|
July 12, 2024
Patient-reported outcomes for the phase 3 FURLONG study of furmonertinib versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic <i>EGFR</i> mutation-positive non-small cell lung cancer
Yuankai Shi, Gongyan Chen, Xiang Wang, et al.
Structure (London, England : 1993)
|
October 15, 2020
The Architecture of Inactivated SARS-CoV-2 with Postfusion Spikes Revealed by Cryo-EM and Cryo-ET
Chuang Liu, Luiza Mendonça, Yang Yang, et al.
The Lancet. Oncology
|
December 20, 2008
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
Ann-Lii Cheng, Yoon-Koo Kang, Zhendong Chen, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 13, 2024
A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanoma
Xiaoting Wei, Zhengyun Zou, Weizhen Zhang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
May 25, 2021
Apatinib Plus Gefitinib as First-Line Treatment in Advanced EGFR-Mutant NSCLC: The Phase III ACTIVE Study (CTONG1706)
Hongyun Zhao, Wenxiu Yao, Xuhong Min, et al.
Chinese Clinical Oncology
|
March 3, 2016
Chinese guidelines on the management of renal cell carcinoma (2015 edition)
Jun Guo, Jianhui Ma, Yan Sun, et al.
BMC Cancer
|
September 2, 2024
Irinotecan plus raltitrexed as second-line treatment in locally advanced or metastatic colorectal cancer patients: a prospective open-label, single-arm, multi-center, phase II study
Yu Cheng, Zan Teng, Yanqiao Zhang, et al.
Page
of 23
Search research articles
Search
Showing results (201-210 of 224) with videos related to
Sort By:
Page
of 23
The Journal of Experimental Medicine
|
August 3, 2021
ASC deglutathionylation is a checkpoint for NLRP3 inflammasome activation
Shuhang Li, Linlin Wang, Zhihao Xu, et al.
Nature Communications
|
April 22, 2022
USP22 regulates lipidome accumulation by stabilizing PPARγ in hepatocellular carcinoma
Zhen Ning, Xin Guo, Xiaolong Liu, et al.
Lung Cancer (Amsterdam, Netherlands)
|
September 13, 2025
Chinese expert consensus on perioperative management of patients with resectable anaplastic lymphoma kinase-fusion non-small cell lung cancer
Hai-Yan Tu, Chun Chen, Chang Chen, et al.
The Lancet Regional Health. Western Pacific
|
July 12, 2024
Patient-reported outcomes for the phase 3 FURLONG study of furmonertinib versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic <i>EGFR</i> mutation-positive non-small cell lung cancer
Yuankai Shi, Gongyan Chen, Xiang Wang, et al.
Structure (London, England : 1993)
|
October 15, 2020
The Architecture of Inactivated SARS-CoV-2 with Postfusion Spikes Revealed by Cryo-EM and Cryo-ET
Chuang Liu, Luiza Mendonça, Yang Yang, et al.
The Lancet. Oncology
|
December 20, 2008
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
Ann-Lii Cheng, Yoon-Koo Kang, Zhendong Chen, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 13, 2024
A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanoma
Xiaoting Wei, Zhengyun Zou, Weizhen Zhang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
May 25, 2021
Apatinib Plus Gefitinib as First-Line Treatment in Advanced EGFR-Mutant NSCLC: The Phase III ACTIVE Study (CTONG1706)
Hongyun Zhao, Wenxiu Yao, Xuhong Min, et al.
Chinese Clinical Oncology
|
March 3, 2016
Chinese guidelines on the management of renal cell carcinoma (2015 edition)
Jun Guo, Jianhui Ma, Yan Sun, et al.
BMC Cancer
|
September 2, 2024
Irinotecan plus raltitrexed as second-line treatment in locally advanced or metastatic colorectal cancer patients: a prospective open-label, single-arm, multi-center, phase II study
Yu Cheng, Zan Teng, Yanqiao Zhang, et al.
Page
of 23